Recent advances and research progress in biomarkers for chronic graft versus host disease

Chronic graft-versus host disease (cGVHD) is a major risk for patients undergoing allogeneic hematopoietic stem cell transplantation. With the emergence of novel therapies and the increased understanding of the mechanisms underlying cGVHD, there are more options for cGVHD treatment. Regardless of improvements in treatment, diagnosis mainly depends on identification of symptoms, which makes precise treatment a challenge. Numerous biomarkers for cGVHD have been validated and have demonstrated strong associations with prognosis and response to treatment. The most common biomarkers mainly include critical types of immune cells, chemokines, cytokines, microRNAs, and autoantibodies, all of which play important roles in the development of cGVHD. Compared to traditional tools, biomarkers have several advantages, for example, they can be applied for early diagnosis, to identify cGVHD risk before onset, and predict which therapy is most likely to benefit patients. In this review, we summarize biomarkers with potential clinical value and discuss future applications. [Display omitted] •Immune cells, cytokines, chemokines, cell-free nucleic acids, and antibodies are novel biomarkers for cGVHD.•Biomarkers can be utilized to diagnose cGVHD at an early stage and to predict the risk of cGVHD prior the onset.•Biomarkers of cGVHD can guide treatment decisions and enhance patient outcomes and quality of life.